90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma

Roberto Ria, Pellegrino Musto, Antonia Reale, Roberto Guariglia, Giuseppe Iodice, Franco Dammacco, Angelo Vacca

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)


Targeted radioimmunotherapy with 90Y-labeled ibritumomab tiuxetan is a novel therapeutic approach for CD20-positive relapsed or refractory non-Hodgkin lymphoma (NHL). Methods: Seven consecutive patients with CD20-positive aggressive NHL who did not fully respond to prior myeloablative chemotherapy were enrolled. A 14.8 MBq (0.4 mCi)/kg dose of 90Y- ibritumomab tiuxetan was administered to all patients, and approximately 100 d afterward 18F-FDG PET/CT was performed to assess response. Results: PET/CT showed a complete response in 5 of 7 patients. Of the 2 nonresponsive patients, 1 showed persistent disease and the other progression. Toxicity included thrombocytopenia in all 7 patients and grade IV neutropenic fever in 1 patient. Conclusion: Despite the small series studied, we suggest that radioimmunotherapy is safe for consolidation in patients treated with high-dose chemotherapy for aggressive NHL and may provide clinical benefit in extensively pretreated patients.

Original languageEnglish
Pages (from-to)891-895
Number of pages5
JournalJournal of Nuclear Medicine
Issue number6
Publication statusPublished - 1 Jun 2011
Externally publishedYes


  • Y-ibritumomab tiuxetan
  • Autologous stem cell transplantation
  • Consolidation therapy
  • Non-Hodgkin lymphoma

Cite this